FIELD: medicine; therapy; endocrinology.SUBSTANCE: present group of inventions concerns treating congenital hyperplasia of adrenal glands. That is ensured by administering an effective amount of CRFreceptor antagonist with a half-dissociation period of more than 50 minutes, specifically compound of 2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl-]N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo-[1,5-a]pyrimidin-7-amine (NBI-77860) or 4-(2-chloro-4-methoxy-5-methylphenyl)--[(1)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl--(2-propyn-1-yl)-2-thiazolamine (SSR-125543).EFFECT: this allows correcting the levels of hormones included in the 'hypothalamic-pituitary axis', in particular 17-hydroxyprogesterone and ACTH, and thus providing normalization of androgen formation with using lower, more physiological doses of hydrocortisone, thereby reducing treatment-related side effects.6 cl, 6 dwg, 2 tbl, 6 ex
CFRRECEPTOR ANTAGONISTS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA